Fulcrum Therapeutics Files 8-K
Ticker: FULC · Form: 8-K · Filed: Sep 12, 2024 · CIK: 1680581
| Field | Detail |
|---|---|
| Company | Fulcrum Therapeutics, INC. (FULC) |
| Form Type | 8-K |
| Filed Date | Sep 12, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-K
TL;DR
Fulcrum Therapeutics filed an 8-K, check for updates.
AI Summary
Fulcrum Therapeutics, Inc. filed an 8-K on September 12, 2024, reporting other events and financial statements. The filing does not contain specific details about the nature of these events or financial figures within the provided text.
Why It Matters
This filing indicates that Fulcrum Therapeutics has made a regulatory submission, which could contain important updates for investors regarding company events or financial status.
Risk Assessment
Risk Level: low — The filing is a standard procedural document without immediate disclosed material impact.
Key Players & Entities
- Fulcrum Therapeutics, Inc. (company) — Registrant
- September 12, 2024 (date) — Date of earliest event reported
- 26 Landsdowne Street (location) — Principal executive offices address
- Cambridge, Massachusetts (location) — Principal executive offices city and state
- 02139 (location) — Principal executive offices zip code
- (617) 651-8851 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The 8-K filing is to report "Other Events" and "Financial Statements and Exhibits" as of September 12, 2024.
What is the official name of the company filing this report?
The official name of the company is Fulcrum Therapeutics, Inc.
On what date was the earliest event reported in this filing?
The earliest event reported was on September 12, 2024.
Where are Fulcrum Therapeutics' principal executive offices located?
Fulcrum Therapeutics' principal executive offices are located at 26 Landsdowne Street, Cambridge, Massachusetts, 02139.
What is the Commission File Number for Fulcrum Therapeutics?
The Commission File Number for Fulcrum Therapeutics is 001-38978.
Filing Stats: 477 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-09-12 12:43:53
Key Financial Figures
- $0.001 — ich registered Common stock, par value $0.001 per share FULC Nasdaq Global Market
Filing Documents
- d844807d8k.htm (8-K) — 25KB
- d844807dex991.htm (EX-99.1) — 16KB
- g844807snap1.jpg (GRAPHIC) — 8KB
- 0001193125-24-217822.txt ( ) — 178KB
- fulc-20240912.xsd (EX-101.SCH) — 3KB
- fulc-20240912_lab.xml (EX-101.LAB) — 18KB
- fulc-20240912_pre.xml (EX-101.PRE) — 11KB
- d844807d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits Exhibit No. Description 99.1 Press release dated September 12, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FULCRUM THERAPEUTICS, INC. Date: September 12, 2024 By: /s/ Alex C. Sapir Name: Alex C. Sapir Title: President and Chief Executive Officer